Aeterna Zentaris Inc (NASDAQ:AEZS)
A growing global biopharmaceutical company focused on endrocrine therapy and oncology, in drug discovery, development and commercialization.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
AndrewGreenBull
(99.14)
Submitted: 6/9/2013 1:46:10 AM :
Start Price:
$2.03
AEZS Score:
-7.96
may see a rebound from solid bottom
Recs
zzlangerhans
(99.76)
Submitted: 3/25/2013 6:44:02 PM :
Start Price:
$1.87
AEZS Score:
-5.66
Somehow I missed the gap down with the failure of the phase III trial of perifosine in myeloma which I had been predicting for months. I'll try and make up for it by greenthumbing the stock at a despondent low. Now that perifosine is out of the picture, Aeterna has an enterprise value of only 5M despite having cytotoxic LHRH analogue AEZS-108 in advanced clinical trials for endometrial, breast, and prostate cancers. Ozarelix and AEZS-130 have less potential but still add depth to the pipeline. Given Aeterna's history of temporarily resuscitating itself, I think it might be reasonable to grab an initial tranche of shares if the price remains stable under 2.
Recs
naughtyguy
(31.44)
Submitted: 3/12/2013 1:44:56 AM :
Start Price:
$2.01
AEZS Score:
+11.79
Why this is worth ANYTHING is beyond me!
Recs
SamsaricSufferer
(< 20)
Submitted: 11/5/2012 10:28:50 PM :
Start Price:
$2.25
AEZS Score:
-31.77
Upcoming Clinical trial catalysts.
Recs
Recs
stainsolution
(22.77)
Submitted: 4/4/2012 7:12:44 PM :
Start Price:
$4.53
AEZS Score:
-75.99
Bottom play. Betting on the future pipeline
Recs
leelu99
(21.21)
Submitted: 4/4/2012 4:51:43 PM :
Start Price:
$4.53
AEZS Score:
-75.99
Stock history around 1.5+ split at .75.... buy!
Recs
TheGreek1966
(< 20)
Submitted: 4/3/2012 2:20:25 AM :
Start Price:
$4.38
AEZS Score:
-72.70
This is a company I have been monitoring for some time. The management team is great and will correct the value lost in no time.
Recs
import2udirect
(< 20)
Submitted: 4/3/2012 1:53:59 AM :
Start Price:
$4.38
AEZS Score:
-72.70
not sure why it seems the whole biomedical field is down looks cheap
Recs
ValueOfTime
(86.21)
Submitted: 4/2/2012 11:16:16 PM :
Start Price:
$4.38
AEZS Score:
-72.70
People buy hype. Stock price is low and the only direction hype can go is up for this stock.
Recs
Recs
RBuskey106
(33.54)
Submitted: 3/14/2012 10:27:15 PM :
Start Price:
$10.20
AEZS Score:
-98.32
Long term....interesting pipeline
Recs
K3VIN0
(< 20)
Submitted: 1/8/2012 4:56:09 AM :
Start Price:
$9.96
AEZS Score:
-108.92
Perifosine is looking good. Pipeline shows potential.
Recs
vaderblue
(21.38)
Submitted: 11/14/2011 7:29:20 PM :
Start Price:
$10.02
AEZS Score:
-111.92
I am convienced AEZS is on the right track but only time will tell. I am betting on AEZS to succeed. After all the shares are cheap and owning some shares may be a good thing in the long run.
Recs
rossklaw
(< 20)
Submitted: 10/3/2011 11:52:10 PM :
Start Price:
$8.46
AEZS Score:
-128.75
Pipeline gamble
Recs
DBurner
(37.80)
Submitted: 9/12/2011 12:12:19 AM :
Start Price:
$11.28
AEZS Score:
-126.21
Deep pipeline and high hopes for perifosene.
Recs
Stef100000
(< 20)
Submitted: 9/10/2011 9:32:26 PM :
Start Price:
$11.28
AEZS Score:
-126.21
Test for perifosine is coming out next year big market
Recs
TMFUltraLong
(99.97)
Submitted: 8/9/2011 12:06:53 AM :
Start Price:
$9.60
AEZS Score:
-123.81
It's a biotech - it will either earn or burn. Based on the research I've done on Aeterna Zentaris and its partnership with Keryx, all signs are pointing that their phase 3 trial will bring a favorable result from the FDA. Aeterna Zentaris has 11 molecules in its pipeline of which 6 are currently in clinical trials. There's plenty of cash here as well, so minimal dilution to shareholders. Fell off a cliff with the rest of the market and down more than 40% in a month. Time to jump aboard on a hopeful dip tomorrow morning.
TMFUltraLong
Recs
almostgem
(< 20)
Submitted: 6/9/2011 2:49:26 PM :
Start Price:
$14.10
AEZS Score:
-112.58
Cancer drug in the pipeline that has been shown to be successful and is now in Stage III testing. If successful, the stock price should soar. Also look to KERX who has agreements with Aeterna Zentraris to market the drug in US MExico and Canada.
the company also has several other drugs in the pipeline and a drug currently released. Even if the drug is not successful, the company has enough to last at least 2 years at the current burn rate.
Recs
HicAZ
(23.62)
Submitted: 5/20/2011 3:30:59 PM :
Start Price:
$13.38
AEZS Score:
-107.95
Superb pipeline of drugs in various stages of development and trials.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 57 : 1 2 3 Next »